News for Livzon Pharmaceutical Group Inc. (1513.HK)

Key Takeaways: Clover Biopharmaceuticals raised $64 million through a new share placement the day after its Covid vaccine was approved in China earlier this month The company could face difficulty as it spends heavily to commercialize the drug, which will compete with four rival products using the same vaccine technology

/PRNewswire/ -- The latest market analysis report titled Immunosuppressants Market by Drug Class and Geography - Forecast and Analysis 2022-2026 has been added...

The inhaled version of Cansino's adenovirus-vectored Covid-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.

/PRNewswire/ -- Technavio's latest research report on the Leuprolide Acetate Market offers a comprehensive analysis on new product launches, the latest trends,...

SAN DIEGO and BASEL, Switzerland, Nov. 16, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, Inc., a biotechnology company developing next-generation…

SAN DIEGO und BASEL, Schweiz, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, Inc., ein Biotechnologieunternehmen, das Zytokin-Immuntherapien...

GuruFocus Article or News written by insider and the topic is about:

A potential COVID-19 vaccine developed by a biotech firm affiliated with China's Livzon Pharmaceutical Group Inc has entered a late-stage trial, Livzon said late on Thursday. A Phase... | August 26, 2021

BEIJING — A potential COVID-19 vaccine developed by a subsidiary of China’s Livzon Pharmaceutical Group Inc appeared safe and able to elicit antibodies in…

BEIJING — China’s medical products regulator has approved clinical trials for a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical…

PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ --  CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative